The above IHC and NGS results indicated shared molecular features between EMPD and breast cancer (overexpression of HR and HER2 proteins), as well as distinctive molecular features of metastatic EMPD (recurrent ERBB2 oncogenes despite low HER2 protein expression). Here, ERBB2 is linked to breast carcinoma.